Recent News

• 03.31.2026 - Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
• 03.17.2026 - Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.
• 02.26.2026 - Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET

Recent Filings

• 03.17.2026 - 3 Initial statement of beneficial ownership of securities
• 03.17.2026 - 8-K Current report
• 03.17.2026 - EX-99.1 EX-99.1
• 03.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.22.2026 - 4/A Statement of changes in beneficial ownership of securities
• 01.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.21.2026 - 8-K Current report
• 01.21.2026 - 4 Statement of changes in beneficial ownership of securities